A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-α2b (Intron A ®
Metastatic renal cell carcinoma (RCC) is resistant to conventional chemotherapy and radiotherapy. A wide variety of immunotherapy protocols using interferon-alpha (IFN-α) and/or interleukin-2 (IL-2) have been developed, however, the response rate remains unsatisfactory at around 10-20% (2, 7). IFN-α represents a large family of structurally related genes consisting of at least 14 subtypes (3) . Each subtype may have different biological activities. We herein report a case of RCC whose pulmonary metastasis initially responded positively to recombinant IFN-α2b, and a good response was again seen using natural IFN-α preparations.
A 49-year-old man presented with gross hematuria and left flank pain in September 1996. Abdominal computerized tomography (CT) revealed a left renal mass measuring 8.8 cm in size. A chest X-ray demonstrated a pulmonary metastatic lesion (Fig. 1A) . The patient underwent a left radical nephrectomy. Based on the pathological findings, it was diagnosed to be clear cell type RCC with a nuclear grade of 2 > 3. The tumor extended into the perinephric fat, with negative margins of resection and no nodal involvement. He was treated with 6.0 × 10 6 I.U. recombinant IFN-α2b (Intron A ® , Schering-Plough Pharmaceuticals Co. Ltd., Osaka, Japan) × 3/week. A complete regression was thus achieved after 4 month (Fig. 1B) . This immunotherapy continued for 4 years with appropriate dose reductions. In September 2002, a new lesion of pulmonary metastasis was found by CT ( Fig. 2A ). IL-2 (Imunace ® , Shionogi Pharmaceuticals Co. Ltd., Osaka, Japan) was administered at 1.4 × 10 6 I.U. × 5/week for 2 months without any response. Therafter, he was treated by 5.0 × 10 6 I.U. natural IFN-α (OIF ® , Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan) × 2/week. The pulmonary lesion demonstrated a partial response after 11 months of treatment (Fig. 2B) . The patient's disease is no longer progressing and he is in a healthy condition, although 8 years have passed since the initial diagnosis of metastatic RCC.
Immunotherapy is a widely accepted standard therapy for metastatic RCC. However, its efficacy remains insufficient at around 10-20% (2, 7). IFN-α is frequently chosen as the standard treatment for initially diagnosed RCC with metastases. When the patient turns out to be resistant to IFN-α, the immunotherapy regimen is sometimes switched to IL-2. Indeed, some patients resistant to IFN-α have been (1, 4) . It is also well known that the production of IFN-α subtypes is regulated by different interferon regulatory factors (6) . Both our findings and those of Horiguchi and Uchida (5) showed differences in the biological activities of the subtypes of IFN-α in a clinical setting. To date there is no means to predict the outcome of immunotherapy. Some patients respond to IFN-α, but not to IL-2, while others respond IL-2 but not IFN-α. Individual-based immunotherapy should thus be carefully taken into consideration. Because IFN-α preparations include different subtypes even among natural type IFN-α preparations, changing the use of IFN-α preparations may thus be a potentially useful option for the successful immunotherapy of RCC.
Table 1 Characterizations of the two types of IFN-α preparations

